Share Email Print

Proceedings Paper

New directions in ALA-PDT
Author(s): Roy H. Pottier; James C. Kennedy; Robert L. Reid
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Certain types of cells may accumulate relatively high concentrations of protoporphyrin IX (PpIX) when exposed to 5- aminolevulinic acid or certain of its derivatives. PpIX is a photosensitizing agent which can be photoactivated in vivo by ultraviolet and/or visible light, thereby initiating a photodynamic reaction that may lead to the destruction of cells and tissues containing high concentrations of PpIX. This process is referred to as ALA-induced PpIX photodynamic therapy (ALA-PDT), a rapidly growing field of research. ALA is effective when administered topically, orally, by intravenous, subcutaneous, or intradermal injection, or by infusion into accessible body cavities. PpIX is the main photosensitizer produced under most conditions, although others may be present also especially during split dose therapy. Multiple wavelength excitation sources are required to produce and subsequently activate the far red absorbing chlorin type photoproducts that are produced under certain conditions.

Paper Details

Date Published: 29 December 1997
PDF: 10 pages
Proc. SPIE 3191, Photochemotherapy: Photodynamic Therapy and Other Modalities III, (29 December 1997); doi: 10.1117/12.297805
Show Author Affiliations
Roy H. Pottier, Royal Military College of Canada (Canada)
James C. Kennedy, Queen's Univ. (Canada)
Robert L. Reid, Queen's Univ. (Canada)

Published in SPIE Proceedings Vol. 3191:
Photochemotherapy: Photodynamic Therapy and Other Modalities III
Kristian Berg; Benjamin Ehrenberg; Zvi Malik; Johan Moan; Abraham Katzir, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?